NCT05305508View on ClinicalTrials.gov

Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19.

PHASE2CompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

May 17, 2022

Primary Completion Date

November 10, 2023

Study Completion Date

February 5, 2024

Conditions
COVID-19 Virus Disease
Interventions
DRUG

Calcium Dobesilate

The treatment (CaD, Calcium Dobesilate 500 mg) will be administered orally twice a day for 7 days.

DRUG

Mannitol

The comparator (placebo, Mannitol 500 mg) will be administered orally twice a day for 7 days.

Trial Locations (1)

1211

Division and Department of Primary Care Medicine, Geneva University Hospitals, Geneva

Sponsors

Collaborators (1)

OM Pharma SA
All Listed Sponsors
collaborator

OM Pharma SA

INDUSTRY

lead

Hervé SPECHBACH

OTHER

NCT05305508 - Assessment of the Efficacy of Calcium Dobesilate vs. Placebo on SARS-CoV-2 Viral Load Amongst Outpatients With COVID-19. | Biotech Hunter | Biotech Hunter